Guard Therapeutics International AB (DPHA) Stock Price & Analysis

DPHA Stock Chart & Stats

SEK 1.13SEK 0.03(2.53%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: SEK 1.05 - SEK 1.13
52-Week Range: SEK 0.88 - SEK 2.35
Previous Close: SEK 1.11
Volume: N/A
Average Volume (3M): 24.23K
Market Cap: SEK 50.56M
Enterprise Value: -SEK 1.84M
Total Cash (Recent Filing): SEK 40.99M
Total Debt (Recent Filing): SEK 0
Price to Earnings (P/E): ―
Beta: 0.48
Next Earnings: Nov 12, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline Focus

A focused lead asset addressing acute kidney injury and oxidative-stress-related renal disease gives the company a clearly defined development strategy. If clinical development succeeds, the therapeutic positioning could support meaningful product differentiation and create a foundation for future commercial growth.

Debt-free Balance Sheet

The absence of debt limits interest obligations and avoids the refinancing pressure associated with leveraged biotechnology companies. This provides greater financial flexibility around research priorities and clinical execution, although the company still needs capital because operations are not self-funding.

Reduced Annual Loss

The narrower loss suggests some improvement in operating discipline or a reduction in cash consumption compared with the prior annual period. Sustaining that improvement could extend the company’s financial runway and make future development spending more efficient, even though profitability remains distant.

Bears Say

No Commercial Revenue

Zero reported revenue indicates that the business has not yet established commercial traction or an operating revenue base. This leaves near-term value creation dependent on successful clinical progress and future product approval, rather than on recurring sales that can independently fund development.

Heavy Cash Burn

Persistent negative operating and free cash flow means the company cannot currently finance its activities from internal cash generation. Continued development therefore depends on external capital, creating financing and potential dilution risk that can remain material through the next several quarters.

Shrinking Equity Base

The substantial contraction in shareholders’ equity, combined with strongly negative return on equity, shows that capital is being consumed rather than compounded. This weakens the financial cushion available for clinical investment and increases the importance of securing additional funding.

DPHA FAQ

What was Guard Therapeutics International AB’s price range in the past 12 months?

Guard Therapeutics International AB lowest stock price was kr 0.88 and its highest was kr 2.35 in the past 12 months.

What is Guard Therapeutics International AB’s market cap?

Guard Therapeutics International AB’s market cap is kr 50.56M.

When is Guard Therapeutics International AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Guard Therapeutics International AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Guard Therapeutics International AB pay dividends?

Guard Therapeutics International AB does not currently pay dividends.

What is Guard Therapeutics International AB’s EPS estimate?

Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Guard Therapeutics International AB have?

Guard Therapeutics International AB has 44,588,066 shares outstanding.

Which hedge fund is a major shareholder of Guard Therapeutics International AB?

Currently, no hedge funds are holding shares in SE:DPHA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description